21/12/2025
Ozempic, a once-weekly injectable medication developed by Novo Nordisk, has been launched in India for the treatment of type-2 diabetes. The active ingredient, semaglutide, is a GLP-1 receptor agonist that helps regulate blood sugar, slow gastric emptying, curb appetite, and improve insulin secretion.
For future updates
*Key Features:*
- _Approved Use_: Ozempic is approved as an adjunct to diet and exercise for adults with type-2 diabetes.
- _Dosage Forms_: Available in 0.25mg, 0.5mg, and 1mg single-use pre-filled pens.
- _Benefits_: Reduces HbA1c levels, aids in weight management, and provides cardiovascular and kidney protection ¹ ² ³.
*Important Notes:*
- Ozempic is not a standalone solution; it requires medical supervision and lifestyle changes.
- Common side effects include nausea, vomiting, and diarrhea.
- Not approved for type-1 diabetes or weight loss in non-diabetic individuals.
